Entia Biosciences Inc
OTC:ERGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Entia Biosciences Inc
Accounts Receivables
Entia Biosciences Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Entia Biosciences Inc
OTC:ERGO
|
Accounts Receivables
$8k
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Estee Lauder Companies Inc
NYSE:EL
|
Accounts Receivables
$1.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Bellring Brands Inc
NYSE:BRBR
|
Accounts Receivables
$246m
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Coty Inc
NYSE:COTY
|
Accounts Receivables
$526.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inter Parfums Inc
NASDAQ:IPAR
|
Accounts Receivables
$320.6m
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
|
elf Beauty Inc
NYSE:ELF
|
Accounts Receivables
$190.3m
|
CAGR 3-Years
42%
|
CAGR 5-Years
34%
|
CAGR 10-Years
24%
|
|
Entia Biosciences Inc
Glance View
Entia Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Sherwood, Oregon. The company went IPO on 2007-11-01. The firm also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The firm's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The firm's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.
See Also
What is Entia Biosciences Inc's Accounts Receivables?
Accounts Receivables
8k
USD
Based on the financial report for Dec 31, 2016, Entia Biosciences Inc's Accounts Receivables amounts to 8k USD.
What is Entia Biosciences Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
-28%
Over the last year, the Accounts Receivables growth was 13%. The average annual Accounts Receivables growth rates for Entia Biosciences Inc have been -7% over the past three years , -28% over the past five years .
